Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Biotechnology

Healthcare
$0.69 -3.42%

-$0.04 today

Market cap
$50.84M
Beta
-0.24
P/E (TTM)
-3.8
EPS (TTM)
-$0.27
52W Low $0.89High $2.09

Volume 0.17M

Average 0.13M

TELO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows in line with its trailing trend

Q1 FY2026 research & development of $467.8K rose 38.8% year over year, behind the +40.4% change in trailing-twelve-month research & development. Sequentially, it fell 63.9% from the prior quarter. Over 3 fiscal years it compounded at +43.0% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +38.8% toward the trailing-twelve-month pace of +40.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$467.8K-63.9% QoQ
Last fiscal yearDec 2025
$2.44M+9.0% YoY
LTMMar 2026
$2.57M+40.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.8%——
1 year+9.0%——
3-year CAGR+43.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
2.44M USD
Year-over-year change
+9.0%
4-year CAGR
+109.5%

Research & Development vs competitors

How TELO compares with its peers on the latest reported figures

  • TELO's LTM Mar 2026 research & development of $2.57M is the 5th highest of the 6 companies compared; the peer median is $16.66M.
  • Its year-over-year change of +40.4% is the highest of 6, against a peer median of -24.7%.
  • Over three fiscal years its annual growth of +43.0% compares with a peer median of -0.5%.
TELO Competitors Peer median
Research & Development for TELO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$124.78M -12.3%-5.5%82.6%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$83.18M -24.7%-0.5%—
INMBINmune Bio, Inc.LTM Mar 2026$16.66M -48.1%+6.6%—
EQEquillium, Inc.LTM Mar 2026$9.91M -70.5%-30.1%—
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$2.57M +40.4%+43.0%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.43M -13.1%+294.0%100.9%
Peer median (excluding TELO) $16.66M-24.7%-0.5%91.7%

Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development126.49K833.21K1.57M2.24M2.44M
Selling, General & Admin11.64K20.94K600.19K9.64M8.1M
Operating Expenses138.13K854.15K3.94M12.24M10.54M
Depreciation & Amortization138.13K854.15K012.24M0
EBITDA00(11.43M)48K(10.41M)
EBITDA Margin—————
Operating Income(138.13K)(854.15K)(3.94M)(12.24M)(10.54M)
Operating Margin—————
Interest Income00048K125.64K
Interest Expense001.64M(4.34M)0
Other Income / Expenses00(9.13M)(4.29M)125.64K
Income Before Tax(138.13K)(854.15K)(13.07M)(16.53M)(10.41M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(138.13K)(854.15K)(13.07M)(16.53M)(10.41M)
Net Margin—————
EPS (Basic)(0.00)(0.03)(0.44)(0.56)(0.33)
EPS (Diluted)(0.00)(0.03)(0.44)(0.56)(0.33)
Weighted Avg Shares29.61M29.61M29.61M29.54M31.65M
Weighted Avg Shares (Diluted)29.61M29.61M29.61M29.54M31.65M

Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ:TELO

Intrinsic Alpha fair value

Locked

Current Price

$0.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.